British rock icons Oasis began their long-awaited reunion tour this month, and it's not hard to see parallels between the ...

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

Pittsburgh, USA-based Viatris, which was formed in 2020 through the merger of Mylan and Pfizer's, saw its shares fall 4.2% to ...

Oppenheimer initiated coverage of the buy now, pay later firm Monday, issuing an "outperform" rating for Affirm stock.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Pfizer recently recalibrated its evaluation score, a nod to shifting trends in the market and its own financial pulse. The ...

Novo Nordisk isn't in the Vanguard Healthcare ETF because it is a Danish company, and the fund focuses on U.S. companies. The ETF would be down even more if it included Novo Nordisk since the company ...

Paul Walsh, founder and managing partner of Walsh Barnes, is winding down his practice after 35 years to launch his own ...

Gold Spot US Dollar, Intel Corporation, Microsoft Corporation, Cisco Systems Inc. Read 's Market Analysis on Investing.com UK.

Analysts are all over Eli Lilly, and most suggest a "Moderate Buy." Sixteen analysts recommend buying, while three say "hold.